Linked Life Data

17623816

Source:http://linkedlifedata.com/resource/pubmed/id/17623816

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2007-9-28
pubmed:abstractText
OBJECTIVE: Peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists (thiazolidinediones [TZDs]) are used for the treatment of diabetes. Bone marrow-derived endothelial progenitor cells (EPCs) improve vascular function and predict cardiovascular risk. The effect of pioglitazone therapy on EPCs was examined. RESEARCH DESIGN AND METHODS AND RESULTS: We performed a prospective, randomized, double-blind study on patients with documented stable coronary artery disease and normal glucose tolerance. Of 54 patients with normal fasting glucose levels, 18 showed impaired glucose tolerance and 36 patients with normal glucose tolerance were randomized to 30-day treatment with pioglitazone (45 mg) or placebo in addition to optimal medical therapy. All patients in the TZD group showed an increase of adiponectin levels as an indicator of compliance (11.4 +/- 1.1 to 36.8 +/- 2.1 microg/ml; P < 0.001). TZD, but not placebo, decreased mean high-sensitivity C-reactive protein to 43 +/- 19% (P < 0.05). Pioglitazone increased CD34(+)/kinase insert domain receptor(+) EPCs to 142 +/- 9% and cultured 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled acetylated LDL(+)/lectin(+) EPCs to 180 +/- 3% (P < 0.05). EPC numbers were not changed in the placebo group. TZD increased the SDF-1-induced migratory capacity to 146 +/- 9% per EPC number (P < 0.05) and upregulated the clonogenic potential of EPCs, increasing the colony-forming units to 172 +/- 12% (P < 0.001). In cultured human EPCs, TZD increased EPC numbers and migration and reduced NADPH-oxidase activity. The TZD effect was reversed by the PPAR gamma antagonist GW9662 and mimicked by treatment with adiponectin. CONCLUSIONS: The PPAR gamma agonist pioglitazone increases the number and function of EPCs in patients with coronary artery disease. The effect represents a potential regenerative mechanism in atherosclerosis and is observed in normoglycemic individuals with stable coronary artery disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1939-327X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2609-15
pubmed:meshHeading
pubmed-meshheading:17623816-Adiponectin, pubmed-meshheading:17623816-Blood Glucose, pubmed-meshheading:17623816-Body Mass Index, pubmed-meshheading:17623816-C-Reactive Protein, pubmed-meshheading:17623816-Coronary Disease, pubmed-meshheading:17623816-Double-Blind Method, pubmed-meshheading:17623816-Endothelium, Vascular, pubmed-meshheading:17623816-Female, pubmed-meshheading:17623816-Glucose Tolerance Test, pubmed-meshheading:17623816-Humans, pubmed-meshheading:17623816-Hypoglycemic Agents, pubmed-meshheading:17623816-Male, pubmed-meshheading:17623816-Middle Aged, pubmed-meshheading:17623816-PPAR gamma, pubmed-meshheading:17623816-Placebos, pubmed-meshheading:17623816-Prospective Studies, pubmed-meshheading:17623816-Reference Values, pubmed-meshheading:17623816-Stem Cells, pubmed-meshheading:17623816-Thiazolidinediones
pubmed:year
2007
pubmed:articleTitle
The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.
pubmed:affiliation
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, 66421 Homburg/Saar, Germany.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't